PPAR Research

PPAR Research / 2007 / Article
Special Issue

PPARs in Lung Biology and Disease

View this Special Issue

Research Article | Open Access

Volume 2007 |Article ID 29632 | 8 pages | https://doi.org/10.1155/2007/29632

Rosiglitazone, an Agonist of PPARγ, Inhibits Non-Small Cell Carcinoma Cell Proliferation In Part through Activation of Tumor Sclerosis Complex-2

Academic Editor: Theodore J. Standiford
Received08 Jan 2007
Revised21 Mar 2007
Accepted27 Mar 2007
Published04 Jun 2007


PPARγ ligands inhibit the proliferation of non-small cell lung carcinoma (NSCLC) cells in vitro. The mechanisms responsible for this effect remain incompletely elucidated, but PPARγ ligands appear to inhibit the mammalian target of rapamycin (mTOR) pathway. We set out to test the hypothesis that PPARγ ligands activate tuberous sclerosis complex-2 (TSC2), a tumor suppressor gene that inhibits mTOR signaling. We found that the PPARγ ligand rosiglitazone stimulated the phosphorylation of TSC2 at serine-1254, but not threonine-1462. However, an antagonist of PPARγ and PPARγ siRNA did not inhibit these effects. Rosiglitazone also increased the phosphorylation of p38 MAPK, but inhibitors of p38 MAPK and its downstream signal MK2 had no effect on rosiglitazone-induced activation of TSC2. Activation of TSC2 resulted in downregulation of phosphorylated p70S6K, a downstream target of mTOR. A TSC2 siRNA induced p70S6K phosphorylation at baseline and inhibited p70S6K downregulation by rosiglitazone. When compared to a control siRNA in a thymidine incorporation assay, the TSC2 siRNA reduced the growth inhibitory effect of rosiglitazone by fifty percent. These observations suggest that rosiglitazone inhibits NSCLC growth partially through phosphorylation of TSC2 via PPARγ-independent pathways.


  1. M. A. Socinski, “Combined modality trials in unresectable stage III non-small cell lung cancer: the cancer and leukemia group B experience,” Seminars in Oncology, vol. 32, 3, pp. S114–S118, 2005. View at: Publisher Site | Google Scholar
  2. C. A. Granville and P. A. Dennis, “An overview of lung cancer genomics and proteomics,” American Journal of Respiratory Cell and Molecular Biology, vol. 32, no. 3, pp. 169–176, 2005. View at: Publisher Site | Google Scholar
  3. S. A. Kliewer, K. Umesono, D. J. Noonan, R. A. Heyman, and R. M. Evans, “Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors,” Nature, vol. 358, no. 6389, pp. 771–774, 1992. View at: Publisher Site | Google Scholar
  4. S. Schmidt, E. Moric, M. Schmidt, M. Sastre, D. L. Feinstein, and M. T. Heneka, “Anti-inflammatory and antiproliferative actions of PPAR-γ agonists on T lymphocytes derived from MS patients,” Journal of Leukocyte Biology, vol. 75, no. 3, pp. 478–485, 2004. View at: Publisher Site | Google Scholar
  5. N. Hirase, T. Yanase, Y.-M. Mu et al., “Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60,” Oncology, vol. 57, 2, pp. 17–26, 1999. View at: Publisher Site | Google Scholar
  6. C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists,” The Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004. View at: Publisher Site | Google Scholar
  7. S. Theocharis, H. Kanelli, E. Politi et al., “Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade,” Lung Cancer, vol. 36, no. 3, pp. 249–255, 2002. View at: Publisher Site | Google Scholar
  8. T. Satoh, M. Toyoda, H. Hoshino et al., “Activation of peroxisome proliferator-activated receptor-? stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells,” Oncogene, vol. 21, no. 14, pp. 2171–2180, 2002. View at: Publisher Site | Google Scholar
  9. S. Han, N. Sidell, P. B. Fisher, and J. Roman, “Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor γ in human lung carcinoma cells,” Clinical Cancer Research, vol. 10, no. 6, pp. 1911–1919, 2004. View at: Publisher Site | Google Scholar
  10. V. G. Keshamouni, R. C. Reddy, D. A. Arenberg et al., “Peroxisome proliferator-activated receptor-? activation inhibits tumor progression in non-small-cell lung cancer,” Oncogene, vol. 23, no. 1, pp. 100–108, 2004. View at: Publisher Site | Google Scholar
  11. S. Han and J. Roman, “Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways,” Molecular Cancer Therapeutics, vol. 5, no. 2, pp. 430–437, 2006. View at: Publisher Site | Google Scholar
  12. X. Wang, A. Beugnet, M. Murakami, S. Yamanaka, and C. G. Proud, “Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins,” Molecular and Cellular Biology, vol. 25, no. 7, pp. 2558–2572, 2005. View at: Publisher Site | Google Scholar
  13. Y. Li, M. N. Corradetti, K. Inoki, and K.-L. Guan, “TSC2: filling the GAP in the mTOR signaling pathway,” Trends in Biochemical Sciences, vol. 29, no. 1, pp. 32–38, 2004. View at: Publisher Site | Google Scholar
  14. S. Han, N. Sidell, S. Roser-Page, and J. Roman, “Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression,” International Journal of Cancer, vol. 111, no. 3, pp. 322–331, 2004. View at: Publisher Site | Google Scholar
  15. S. Han, Z. M. Lei, and C. V. Rao, “Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua,” Endocrinology, vol. 137, no. 5, pp. 1791–1797, 1996. View at: Publisher Site | Google Scholar
  16. J. J. Schlezinger, J. K. Emberley, and D. H. Sherr, “Activation of multiple mitogen-activated protein kinases in pro/pre-B cells by GW7845, a peroxisome proliferator-activated receptor γ agonist, and their contribution to GW7845-induced apoptosis,” Toxicological Sciences, vol. 92, no. 2, pp. 433–444, 2006. View at: Publisher Site | Google Scholar
  17. M. Li, T. W. Lee, T. S. K. Mok, T. D. Warner, A. P. C. Yim, and G. G. Chen, “Activation of peroxisome proliferator-activated receptor-γ by troglitazone (TGZ) inhibits human lung cell growth,” Journal of Cellular Biochemistry, vol. 96, no. 4, pp. 760–774, 2005. View at: Publisher Site | Google Scholar
  18. Y. Li, K. Inoki, P. Vacratsis, and K.-L. Guan, “The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3,” Journal of Biological Chemistry, vol. 278, no. 16, pp. 13663–13671, 2003. View at: Publisher Site | Google Scholar
  19. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at: Publisher Site | Google Scholar
  20. A. Galli, E. Ceni, D. W. Crabb et al., “Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPAR? independent mechanisms,” Gut, vol. 53, no. 11, pp. 1688–1697, 2004. View at: Publisher Site | Google Scholar
  21. C.-W. Shiau, C.-C. Yang, S. K. Kulp et al., “Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR?,” Cancer Research, vol. 65, no. 4, pp. 1561–1569, 2005. View at: Publisher Site | Google Scholar
  22. U. Valentiner, M. Carlsson, R. Erttmann, H. Hildebrandt, and U. Schumacher, “Ligands for the peroxisome proliferator-activated receptor-γ have inhibitory effects on growth of human neuroblastoma cells in vitro,” Toxicology, vol. 213, no. 1-2, pp. 157–168, 2005. View at: Publisher Site | Google Scholar
  23. P. Ferruzzi, E. Ceni, M. Tarocchi et al., “Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 3, pp. 1332–1339, 2005. View at: Publisher Site | Google Scholar
  24. S.-I. Kawaguchi, K. Harada, Supriatno, H. Yoshida, and M. Sato, “Overexpression of tuberous sclerosis complex 2 exerts antitumor effect on oral cancer cell lines,” Oral Oncology, vol. 39, no. 8, pp. 836–841, 2003. View at: Publisher Site | Google Scholar
  25. A. Y. Choo, P. P. Roux, and J. Blenis, “Mind the GAP: Wnt steps onto the mTORC1 train,” Cell, vol. 126, no. 5, pp. 834–836, 2006. View at: Publisher Site | Google Scholar
  26. C. J. Potter, L. G. Pedraza, and T. Xu, “Akt regulates growth by directly phosphorylating Tsc2,” Nature Cell Biology, vol. 4, no. 9, pp. 658–665, 2002. View at: Publisher Site | Google Scholar
  27. K. Inoki, T. Zhu, and K.-L. Guan, “TSC2 mediates cellular energy response to control cell growth and survival,” Cell, vol. 115, no. 5, pp. 577–590, 2003. View at: Publisher Site | Google Scholar
  28. M. Nellist, M. A. Goedbloed, and D. J. J. Halley, “Regulation of tuberous sclerosis complex (TSC) function by 14-3-3 proteins,” Biochemical Society Transactions, vol. 31, no. 3, pp. 587–591, 2003. View at: Publisher Site | Google Scholar
  29. S. D. Shumway, Y. Li, and Y. Xiong, “14-3-3β binds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin,” Journal of Biological Chemistry, vol. 278, no. 4, pp. 2089–2092, 2003. View at: Publisher Site | Google Scholar
  30. S. Das, A. Tosaki, D. Bagchi, N. Maulik, and D. K. Das, “Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 3, pp. 980–988, 2006. View at: Publisher Site | Google Scholar
  31. H. Ishida, K. Ohkawa, A. Hosui et al., “Involvement of p38 signaling pathway in interferon-a-mediated antiviral activity toward hepatitis C virus,” Biochemical and Biophysical Research Communications, vol. 321, no. 3, pp. 722–727, 2004. View at: Publisher Site | Google Scholar

Copyright © 2007 ShouWei Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

0 Views | 0 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.